Reata Pharmaceuticals Inc (RETA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access RETA Annual Balance Sheets →
This page allows investors to track Reata Pharmaceuticals Inc's balance sheet development across multiple reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2023)
(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Assets
Cash & cash equivalent48.84
Marketable Securities, Current SH281.37
Cash & Short-term Investments329.00
Accounts receivable22.66
Inventories2.94
Prepaid Expense And Other Assets Current46.03
Total Current Assets401.85
Equipment/Property/Plant Net11.30
Other Assets, Noncurrent12.00
Total Assets502.59
Liabilities
Accounts Payable, Current AC19.86
Accrued Liabilities, Current AC25.14
Other Liabilities, Current80.10
Total Current Liabilities125.09
Long-term debt73.13
Total Long-term Debt73.13
Other liabilities, Noncurrent0.00
Operating Lease Liability Current2.46
Operating Lease Liability Noncurrent90.42
Liability For Sale Of Future Royalties Carrying Amount Net0.00
Total Liabilities198.22
Stockholders' Equity
Common Stock Value0.03
Additional Paid In Capital Common Stock1,577.90
Retained Earnings / Accumulated Deficit-1,490.65
Other Equity0.01
Common Stockholder's Equity87.29
Total Stockholder's Equity87.29
Liabilities & Stockholder's Equity502.59
4 historic quarters locked

Sign in to unlock the full Reata Pharmaceuticals Inc balance sheet history.

About Reata Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-23-039225

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.